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In this issue of Cancer Cell, Mumm et al. demonstrate that pegylated IL-10 increases CD8+ T cell numbers,
IFN-g secretion, and cytotoxicity in established tumors, enhancing antigen presentation machinery and sup-
pressing tumor growth. This approach may enhance T cell immune responses in cancers with reduced T cell
infiltration.IL-10 is an anti-inflammatory cytokine
produced primarily by macrophages,
regulatory T cells, and epithelial cells
(Ouyang et al., 2011). IL-10 has pleio-
tropic effects in immunoregulation and
inflammation, inhibiting the production of
multiple, diverse inflammatory mediators
(e.g., IL-12, MHC class II antigens and
costimulatory molecules) from activated
macrophages and dendritic cells—a
process requiring STAT3 activation. It
also downregulates the expression of
Th1 cytokines (such as IFN-g, TNF,
IL-1b, and IL-6) and impairs secondary
CD8+ T cell responses. More generally,
IL-10 enhances B cell survival, prolifera-
tion, and antibody production. IL-10
deficiency in mice suggests the function
of this cytokine as an essential immunore-
gulator in the intestinal tract, and muta-
tions in IL-10 are also associated with an
increased susceptibility to HIV-1 infection
and rheumatoid arthritis.
The dual functions of IL-10 and IFN-g
in antitumor immunity and immunoregu-
lation have been recognized for some
time (Wilke et al., 2011). It must be said
that much confusion has surrounded
the biological function of cytokines in
tumor immunity because the effects of
neutralizing or deleting an endogenous
cytokine are often quite distinct from
those when the same cytokine is exoge-
nously administered or ectopically-ex-
pressed from the tumor. IL-23 is a case
in point where blockade or deletion of
the host cytokine leads to reduced
tumor incidence (Teng et al., 2010), yet
paradoxically, exogenous or ectopic
cytokines also cause tumor regression
(Lo et al., 2003). Here, however, Mumm
et al. (2011; this issue of Cancer Cell)present a series of quite concordant
results indicating that host IL-10 and
exogenous pegylated IL-10 (PEG-IL-10)
promote CD8+ T cell control of devel-
oping or established tumors, respec-
tively. The data regarding therapeutic
PEG-IL-10 are novel and convincing.
Mumm et al. (2011) clearly show that
PEG-IL-10 increases CD8+ T cell
numbers in large transplanted and spon-
taneous tumors and reduces tumor size
(Figure 1). It is unclear from the results
presented whether PEG-IL-10 increases
T cell infiltration or increases survival or
proliferation of T cells in the tumor—IL-
10 has been shown to do the latter. The
results showing suppression of large
HER2-driven mammary cancers by
PEG-IL-10 are quite remarkable for
a single therapy. In correlation, PEG-IL-
10 directly induces granzymes and IFN-
g in CD8+ T cells and antigen presenta-
tion indirectly via CD8+ T cell-derived
IFN-g. Mumm et al. (2011) also show
that IL-10 expression correlates with the
expression of granzymes, IFN-g, and
MHC molecules in human tumors. The
data suggest that PEG-IL-10 might not
be very effective for tumors that lack
responsiveness to IFN-g, a well-charac-
terized immune escape mechanism.
IL-10-deficient mice are known to
develop colitis and colorectal cancer in
a strain dependent manner. In concert,
in the colitis and skin papilloma resistant
C57BL/6 strain, Mumm et al. (2011)
clearly observed that IL-10-deficient
mice were more sensitive to DMA/TPA-
induced papilloma, whereas human
IL-10 transgenic mice were more resis-
tant. These data are consistent with an
important role for host IL-10 in controllingCancer Cell 20, Dtumor initiation but are difficult to recon-
cile with some other studies using this
carcinogen-induced skin tumor model.
Notably, innate gd T cells have been
shown to be critical host protective
effector cells in the DMBA/TPA-induced
skin papilloma model, rather than CD8+
ab T cells (Girardi et al., 2003). Further-
more, Xiao et al. (2009) have shown in
the 129 strain that host IFN-g promotes
papilloma development. Both of these
previous findings are inconsistent with
Mumm et al’s major hypothesis that
IL-10 reduces skin and other tumor
development via CD8+ T cell and IFN-g-
dependent mechanisms. One has to be
cautious in making general conclusions
from mouse models that are strain-
dependent. In a larger series of studies
performed using methylcholanthrene,
a carcinogen that induces fibrosarcomas,
host IL-10 was shown to promote tumor
formation (Swann et al., 2008). To date,
there has been no report linking IL-10
and IL-10RA expression as a positive
correlate for survival of cancer patients.
In a large cohort of colorectal cancer
patients where effector memory T cells
correlate tightly with disease stage and
improved prognosis, there was no corre-
lation between expression of IL-10 and
IL-10 receptor and a positive prognosis
(JeromeGalon, personal communication).
However, it will be important in future
studies to clarify whether a positive corre-
lation exists in other patient cohorts,
which would strengthen the clinical
relevance of IL-10 and its role in cancer
immunity. Although it is not trivial, as-
sessing conditional deletion of IL-10 in
many other mouse models of cancer
might yield a clearer picture of the roleecember 13, 2011 ª2011 Elsevier Inc. 691
Figure 1. A New IL-10 Cancer Therapeutic
The study by Mumm et al. (2011) proposes that treatment with PEG-IL-10 may be effective in increasing CD8+ T cell numbers in the tumor microenvironment.
(A) Systemic PEG-IL-10may bind either CD8+ T cells (middle right) or other IL-10R leukocytes (middle left) in the tumormicroenvironment. Following an increase in
intratumor CD8+ T cell numbers by a number of possible mechanisms detailed in inset (B), the boosted adaptive immune system may combine well with other
immunotherapeutic strategies such as cancer vaccination/adoptive cellular transfer (ACT) to enhance effector CD8+ T cell numbers or anti-CTLA-4 or anti-PD-1
blockade of T cell checkpoint molecules to convert exhausted CD8+ T cells into effector CD8+ T cells in the tumor microenvironment (middle right). The antitumor
or protumor effects of PEG-IL-10 via other IL-10R-expressing cells remain unclear (middle left). PEG-IL-10 therapy may also lead to lymphocyte and monocyte
infiltration and varying degrees of toxicity/immunopathology in different normal tissues (left panel). Inset (B) in the tumor, PEG-IL-10 binds IL-10R more highly
expressed on CD8+ T cells triggering perforin (pfp)/granzyme B (grzB) production and IFN-g release. These may act directly on tumor cells or IFN-g indirectly
by enhancing tumor MHC class I or antigen presentation (via MHC class I and II) on antigen presenting cells (APC).
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Mumm et al. (2011) showed that IL-10
directly induced cytolytic molecules in
CD8+ T cells and antigen presentation
indirectly through CD8+ T cell-derived
IFN-g. However, other studies have re-
ported that administration of IL-10 can
result in increased NK cell-mediated
rejection of metastases independently of
T cells (Zheng et al., 1996). Given that
IL-10RA is expressed on a variety of
different immune cells including NK cells,
CD4 T cells, neutrophils, monocytes, and
macrophages, IL-10 could potentially
induce antitumor responses through
many different cellular immune subsets.
This further highlights the need to deter-
mine whether other immune subsets can
contribute to IL-10-mediated rejection
in a number of clinically relevant tumor
models.
The central tenet by Mumm et al. (2011)
is that T cell polarization and the effector
response, rather than immune recognition
per se, are deregulated by tumors. They
postulate that redirecting T cells in tumor692 Cancer Cell 20, December 13, 2011 ª20pathology into cytotoxic effectors may
represent a powerful new immunothera-
peutic approach against late stage
cancer. Their current work raises the inter-
esting possibility that new combination
strategies may be designed to capitalize
on the adaptive tumor-specific immunity
generated by PEG-IL-10. In particular,
the ability of PEG-IL-10 to increase tumor
infiltration of CD8+ T cells should effec-
tively combine with approaches,
approved or in late phase clinical trials,
that enhance the function of tumor-
specific CD8+ T cells that have reached
the tumor but fail to act (Figure 1). Such
therapeutics might include antibodies tar-
geting CTLA4, PD-1/PD-L1, TIM3, or
CD137. Indeed, it will be interesting to
determine the level of expression of these
proteins on tumor-specific and infiltrating
T cells following PEG-IL-10 therapy. In
addition, some cancer vaccines that stim-
ulate decent systemic numbers of tumor-
specific T cells might benefit when
combined with PEG-IL-10. One decade
ago, a report elegantly showed that injec-
tion of IL-10 just after a booster vaccine11 Elsevier Inc.significantly enhanced antitumor immu-
nity (Fujii et al., 2001). The combination
of each of these approaches with PEG-
IL-10 must now be tested in preclinical
mouse models of cancer.
A very important consideration for the
translation of PEG-IL-10 into the clinic is
potential toxicities and immunopathol-
ogies that might be caused by this
formulation. The authors reported that
PEG-IL-10 mediated some lymphocyte
and monocyte infiltrations and apoptosis
of epithelial cells in organs such as the
liver and pancreas. If more generalized,
these pathologies may be quite dose-
limiting and concerning. The authors do
show an increased IL-10RA expression
on tumor-infiltrating CD8+ T cells
compared with other immune cells, but
this difference was quite modest. Given
concerns over the safety profile of some
other immunotherapeutics, mechanisms
underlying the toxicities of PEG-IL-10
require closer scrutiny.
In summary, PEG-IL-10 may represent
a new avenue to improve oncology
outcomes, and the debate concerning
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Previewsthe immunostimulatory versus immuno-
suppressive effects of IL-10 remains alive
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BRCA1 is a crucial human breast and ovarian cancer tumor suppressor gene. The article by Drost et al. in this
issue of Cancer Cell together with a recent paper in Science now provide a clearer picture of how this large
and complex protein suppresses tumorigenesis.Breast and ovarian cancer are major
causes of mortality and morbidity in the
developed world. Up to 10% of all breast
cancers are due to the inheritance of
germline mutations in two breast cancer
susceptibility loci (BRCA1 and BRCA2).
In fact, mutations in BRCA1 account for
up to 80% of families with breast and
ovarian cancer predisposition and there-
fore pose a significant burden to human
health. The BRCA1 gene encodes a large
polypeptide that interacts with its consti-
tutive binding partner BARD1. There is
a body of evidence indicating that the
BRCA1-BARD1 heterodimer is a crucial
regulator of the cellular response to
DNA damage. Loss of BRCA1 results in
genomic instability, probably due to an
impaired DNA damage response. It is
therefore likely that BRCA1 suppresses
tumorigenesis by preventing genetic
instability.
Two regions of the BRCA1 protein are
thought to be critical to this function: first,
an N-terminal RING domain that has E3ubiquitin ligase activity that is potentiated
through its interaction with BARD1; and
second, the C-terminal BRCT domain
that mediates the specific interaction
with the phosphorylated form of DNA
repair factors (Figure 1) (Huen et al.,
2010). However, the mechanism by which
these two regions contribute to tumor
suppression has not been clarified. Two
recent papers provide this critical informa-
tion (Shakya et al., 2011; Drost et al., 2011
[this issue of Cancer Cell]). In addition the
conclusionsdrawn from thesenewstudies
have potential clinical implications for the
treatment of patients with breast cancer
in which BRCA1 has been mutated.
Using mice, Shakya et al. (2011)
dissected the function of the RING
domain associated ubiquitin ligase
activity and the BRCT domain. In partic-
ular they assessed how these two regions
of BRCA1 contributed to embryonic
development (the homozygous Brca1
null mutation is embryonic lethal) and
tumor suppression. The E3 ligase activityof the RING domain has previously been
implicated in the DNA damage response
(Ruffner et al., 2001) and more recently
in the maintenance of heterochromatin
(Zhu et al., 2011). Furthermore, human
cancer predisposing mutations often
clustered in this region with some, such
as BRCA1C61G, abrogating E3 ubiquitin
ligase activity. Cellular studies have
shown that BRCA1 localized to DNA
damage induced foci which also con-
tained polyubiquitinated substrates
(Morris and Solomon, 2004). Though
compelling, these lines of evidence are
correlative and lack genetic evidence
directly linking the E3 ubiquitin ligase
activity to the role of BRCA1 in DNA repair
and in tumor suppression. Shakya et al.
(2011) therefore engineered a point muta-
tion within the RING finger domain of
BRCA1. This Brca1I26A mutation results
in the loss of the E3 ligase activity of
BRCA1 but does not compromise either
the stability of the protein or its interaction
with BARD1. Previous work from theecember 13, 2011 ª2011 Elsevier Inc. 693
